March‐18 1 Toe‐Morrow Never Dies! An Approach to the Diabetic Foot 2018 Banff ASA Dr. Michael Yan, MD, CCFP Assistant Clinical Professor Department of Family Medicine University of Alberta Faculty/Presenter Disclosure • Faculty/Presenter: Dr. Michael Yan • Relationships with commercial interests: Grants/Research Support: Not Applicable Speakers Bureau/Honoraria: Not Applicable Consulting Fees: Not applicable Other: This presentation has received support from the Alberta College of Family Physicians in the form of a speaker fee and/or expenses.
35
Embed
Never Dies!€¦ · • Patient education • Professionally fitted therapeutic footwear to – reduce plantar pressure – accommodate foot deformities K. Bowering, J.M. Embil. CDA
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
March‐18
1
Toe‐Morrow Never Dies!An Approach to the Diabetic Foot
2018 Banff ASADr. Michael Yan, MD, CCFPAssistant Clinical ProfessorDepartment of Family MedicineUniversity of Alberta
Faculty/Presenter Disclosure
• Faculty/Presenter: Dr. Michael Yan
• Relationships with commercial interests:
Grants/Research Support: Not Applicable
Speakers Bureau/Honoraria: Not Applicable
Consulting Fees: Not applicable
Other: This presentation has received support from the Alberta College of Family Physicians in the form of a speaker fee and/or expenses.
March‐18
2
ACFP 63rd ASADisclosure of Commercial Support
This program has received financial support in the form of sponsorship from:
• Potential for conflict(s) of interest: Those speakers/faculty who have made COI disclosure are noted in the 63rd ASA Program and on the Salon A/B slide scroll.
Mitigating Potential Bias
• ACFP: → The ACFP’s Sponsorship Guidelines apply to ASA Sponsorship. The ACFP abides by the College of
Family Physicians of Canada’s Understanding Mainpro+ Certification Guidelines, the Canadian Medical Association’s Policy Guidelines for Physicians in Interactions With Industry and the Innovative Medicines Canada Code of Ethical Practices (2016). As a non‐profit organization, the ACFP complies with Canada Revenue Agency regulations. When deliberating acceptance of sponsorship, the ACFP considers and accepts sponsorship only from those whose products, services, policies, and values align with the ACFP vision, values, goals, and strategies priorities.
• ASA Planning Committee: → Consideration was given by the 63rd ASA Planning Committee to identify when Planning
Committee members’ and speakers’ personal or professional interests may compete with or have actual, potential, or apparent influence over program content.
→ Material/Learning Objectives and/or session description were developed and reviewed by a Planning Committee composed of experts/family physicians responsible for overseeing the program’s needs assessment and subsequent content development to ensure accuracy and fair balance.
→ The 63rd ASA Planning Committee reviewed Sponsorship Agreements to identify any actual, potential or apparent influence over the program.
→ Information/recommendations in the program are evidence‐ and/or guidelines‐based, and opinions of the independent speakers will be identified as such.
March‐18
3
Objectives
• 1. demonstrate an approach to screening and classification for the high‐risk diabetic foot
• 2. assess a foot ulcer in a diabetic patient and select appropriate initial management
• 3. select appropriate footwear and community resources for ulcer prevention
March‐18
4
March‐18
5
March‐18
6
Diabetic foot: the numbers
• By 2020, 3.7 million people in Canada will have a known diagnosis of diabetes.1
• People with diabetes have about a 15‐25% lifetime risk of a foot ulcer.2,3
• People with diabetes have a 23‐fold higher risk of lower extremity amputation.2
• 85% of lower leg amputations were preceded by an ulcer 4
1. Canadian Diabetes Association, 20092. Alavi A. et al (2013) Diabetic Foot Canda 1:13‐173. Singh N. et al (2005) JAMA 293:217‐284. Orsted HL, et al. Best Practice Recommendations for the Prevention, Diagnosis and Treatment
of Diabetic Foot Ulcers: Update 2006. Wound Care Canada. 2006;4(1) 57‐71.
Diabetes Foot Care Clinical Pathway Diabetes Foot Screening Tool
20710(Rev2017-03)
EXAM FINDINGS R L RISK
SKIN
Normal intact skin – healthy or dry *check in between toes LOW Callus/Corn/Fissure/Crack not bleeding or draining
MODERATE Prior history of Diabetic Foot Ulcer(s) ulcer in remission Blister = B or Hemorrhagic callus = HC
HIGH Fissure or Crack Bleeding or draining = F Diabetic Foot Ulcer – Not infected and/or with intact dry black eschar = U Infected Diabetic Foot Ulcer or wet gangrene URGENT
NAILS Normal well-kept with minimal discoloration LOW Missing, sharp, unkept, thickened, long or deformed
MODERATE Infected ingrown nail
STRUCTURE ANATOMY
Normal no noted visual abnormalities LOW Decreased range of motion at ankle or toe joint
MODERATE Deformities Bunion/Hammer or claw toes/overlapping toes Structure Fallen Arch/ Rocker bottom foot/stable Charcot foot Previous amputation X over location or draw/describe on diagram Redness over any structural deformities pressure related HIGH Red, hot painful joint or acute Charcot foot URGENT
SENSATION Testing for LOPS
Normal sensation using 10 g monofilament at the 5 predetermined sites LOW
Sensation of numbness/tingling/throbbing/burning MODERATE
Absent or altered sensation at one or more of the five sites Acute onset of pain in a previously insensate foot URGENT
VASCULAR Testing for Arterial Compromise
Normal pulses normal capillary refill LOW Signs of Ischemia (PAD) Cool skin with pallor, cyanosis or mottling, and/or dependent rubor
HIGH
One or more pulses not palpable or audible (Doppler) Absent pedal pulses with cold white painful foot or toes URGENT
Inappropriate Footwear causing pressure/skin breakdown HIGH
Instructions: Refer to Health Provider’s Guide to Diabetes Foot Screening Mark ulceration location (U). Mark other areas of specific concern: blister (B), draining fissure/crack (F), hemorrhagic callus (HC), and previous amputation (X).
Sensation Testing (monofilament) RIGHT LEFT Identify any wounds and location on the foot or toe(s)
Sibbald RG et al. Best Practice Recommendations for Preparing the Wound Bed: Update 2006. Wound Care Canada. 2006;4(1):15‐29.
March‐18
16
Debridement
• Not a sterile procedure
• Can score (tic tac toe board)
• Can fully debride – may need freezing!!
• Remove debris, necrotic tissue deroof an ulcer
• Need a scalpel, forceps, scissors
• Debride the peel without cutting the pulp
March‐18
17
Debridement
March‐18
18
Infection and Inflammation
Person with Diabetic Foot Ulcer
Treat the Cause Local Wound Care
Debridement
Infection/Inflammation
Moisture Balance Edge Effect
Patient‐centered Concerns
Adapted from Sibbald RG et al. Preparing the wound bed 2003. Ostomy/Wound Management. 2003:49(11):24‐51
• Is this wound infected?
• What dressings can be used to fight infections?
March‐18
19
Infection
Contaminated/ColonisedCritically colonised
Infected
Bacterial count rising = signs of infection increase
Adapted from Flanagan 2003
Bac
teria
l cou
nt
Classical Signs of Overt Wound Infection
Wound Breakdown
Warmth
Erythema Pain
Edema
Discharge
Lymphangitis/Cellulitis
March‐18
20
Infection and Inflammation: NERDS and STONEES
• NERDS
– Non‐healing
– Exudate
– Red, friable granulation
– Debris on surface
– Smell
• STONEES
– Size increased
– Temperature increased >3 F deg
– Os: probes to bone
– New/satellite ulcers
– Erythema
– Exudate
– Smell (even worse)Sibbald RG, Woo K, Ayello EA. Increased Bacterial Burden and Infection: The Story of NERDS and STONES. ADV SKIN WOUND CARE 2006;19:447‐61
What bugs are we treating?
• < 30 days: skin bacteria
• > 30 days: polymicrobial
• Staphylococcus aureus, MRSA
• Streptococcus spp
• Pseudomonas spp
• Anaerobes
• Why do we swab?
• How do we swab: Levine method
March‐18
21
Topical Antimicrobials
• Ionized Silver (look for high release of silver)
• Cadexamer iodine
• Mupirocin ointment or cream
• Fucidic acid cream (not ointment)
• Silver sulfadiazine cream
• Medical grade honey
• Polyhexamethyl biguanide (PHMB)
Topicals to Avoid
• Neomycin, bacitracin
• Fucidic acid Ointment (lanolin)
• Lanolin, Bacitracin, Neomycin can be sensitizers: contact dermatitis.
Hydrogel plus semi‐occlusive foam dressingHydrocolloidsFilms
For more details:
Okan D et al. The Role of Moisture Balance in Wound Healing. Adv Skin Wound Care. 2007;20:39‐53.
Fonder MA et al. Treating the chronic wound: A practical approach to the care of nonhealingwounds and wound care dressings. J Am Acad Dermatology 2008;58:185‐206.
Person with Diabetic Foot
Ulcer
Treat the Cause
‐Chronic Venous
Insufficiency
‐Pressure
‐Ischemia
Local Wound Care
DebridementInfection/Inflam
mationMoisture Balance
Edge Effect
Patient‐centered Concerns
Treat the Cause
Adapted from Sibbald RG et al. Preparing the wound bed 2003. Ostomy/Wound Management. 2003:49(11):24‐51
March‐18
24
Lower Limb Assessment
• Ankle/Brachial Pressure Index (ABI)
• Toe Pressures or Photoplethysmography (PPG)
• Arterial doppler study (ultrasound)
• Angiography (CT or MRI)
March‐18
25
CAWC Wound Care Slide Series
Arterial assessment• Doppler/ABPI
ABI and Toe Pressures
ABI PPG
Normal 0.8 to 1.2 > 80 mmHg
Moderate ischemia 0.5 to 0.8 50‐80 mmHg
Severe ischemia < 0.5 < 50 mmHg
Healable: ABI greater than 0.5, toe pressure greater than 50 mmHg
Adapted from:‐Burrows C, et al. Best Practice Recommendations for the Prevention and Treatment of Venous Leg Ulcers Update 2006. Wound Care Canada. 2006;4(1):45‐55.‐Sibbald, RG et al. Best Practice Recommendations for Preparing the Wound Bed. Wound Care Canada. 2006;4(1): 15‐29.
March‐18
26
Edema: Compression Therapy
• Elastic compression wraps
• Inelastic compression wraps
– Short stretch bandages
– Unna or Duke boot
• Stockings?
• 30‐40 mmHg
• Revascularization in case of ischemia
• Offloading in case of pressure
March‐18
27
Trauma
Remodeling
Inflammation
Proliferation
Maturation
Hemostasis
Defense against bacteria Debridement
PlateletsCoagulation factors
Growth factors
Neutrophils Enzymes Macrophages Proteases
Formation of tissue
Migration of epithelial cells
Angiogenesis
Growth factors
• Consider novel treatments when despite optimal wound care, the wound still does not heal
• A 20% to 40% reduction of wound area in 2 and 4 weeks is likely to be a reliable predictive indicator of healing weeks. (Flanagan 2003)